دورية أكاديمية
Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus
| العنوان: | Antibodies to domain I β2 -glycoprotein 1 in patients with antiphospholipid syndrome and systemic lupus erythematosus |
|---|---|
| المؤلفون: | F. A. Cheldieva, T. M. Reshetnyak, M. V. Cherkasova, S. I. Glukhova, A. M. Lila, E. L. Nasonov |
| المصدر: | Научно-практическая ревматология, Vol 60, Iss 3, Pp 353-359 (2022) |
| بيانات النشر: | IMA PRESS LLC, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Diseases of the musculoskeletal system |
| مصطلحات موضوعية: | antiphospholipid antibodies, antiphospholipid syndrome, antibodies to domain i β2 -glycoprotein 1, pregnancy morbidity, thrombosis, Diseases of the musculoskeletal system, RC925-935 |
| الوصف: | The study of antiphospholipid antibodies (aPL), not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood.The aim of this study – to determine the clinical significance of IgG antibody testing for domain I β2 -glycoprotein 1 (β2 -GP1DI) – IgG anti-β2 -GP1DI in patients with APS with and without SLE.Materials and methods. The study included 187 patients with APS with or without SLE, 49 patients formed a comparison group, and 100 relatively healthy individuals formed a control group. IgG/IgM antibodies to cardiolipin and IgG/ IgM anti-β2 -GP1 were determined by enzyme immunoassay (ELISA) in patients with or without APS, and IgG antiβ2 -GP1DI was determined by chemiluminescence assay in all patients and controls.Results. IgG anti-β2 -GP1DI was detected in 37 (71%) of 52 patients with primary APS (PAPS), in 6 (50%) of 12 patients with probable APS, in 42 (71%) of 59 patients with SLE+APS, in 17 (26%) of 64 patients with SLE, in 1 (2%) of comparison group and in none of control group. IgG anti-β2 -GP1DI was significantly associated with PAPS and SLE+APS compared with patients with SLE (p=0.0002 and p=0.0001, respectively). The association of IgG anti-β2 -GP1DI with clinical manifestations of APS (thrombosis (χ2 =9.69; p=0.001) and obstetric pathology (χ2 =4.19; p=0.04)) was detected. There was a significant association of IgG anti-β2 -GP1DI with arterial thrombosis (χ2 =8.84; p=0.002) and with late gestational obstetric pathology (χ2 =6.35; p=0.01). High specificity of IgG anti-β2 - GP1DI depending on the diagnosis and clinical manifestations of APS was noted despite low sensitivity: specificity for thrombosis was 84%, for obstetric pathology – 94%, for APS – 89%. Isolated IgG anti-β2 -GP1DI positivity was reported in 2% of 50 aPL negative patients and was not associated with APS manifestations.Conclusion. The frequency of IgG anti-β2 -GP1DI detection was higher in patients with APS compared to patients with SLE, comparison group and control (p˂ 0.05). Positive IgG anti-β2 -GP1DI values were significantly associated with thrombotic complications and with obstetric pathology (χ2 =8.84; p=0.002 and χ2 =6.35; p=0.01). Specificity of IgG anti-β2 -GP1DI for APS and its clinical manifestations (thrombosis and obstetric pathology) was higher than sensitivity: 89%, 94%, and 84%, respectively. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Russian |
| تدمد: | 1995-4484 1995-4492 |
| Relation: | https://rsp.mediar-press.net/rsp/article/view/3184; https://doaj.org/toc/1995-4484; https://doaj.org/toc/1995-4492 |
| DOI: | 10.47360/1995-4484-2022-353-359 |
| URL الوصول: | https://doaj.org/article/82a0179bb1f546838374aa7332e21aa7 |
| رقم الأكسشن: | edsdoj.82a0179bb1f546838374aa7332e21aa7 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 19954484 19954492 |
|---|---|
| DOI: | 10.47360/1995-4484-2022-353-359 |